XTalks

JANUARY 19, 2024

Regulatory bodies have demonstrated preparedness for the surge in radiopharmaceuticals as evidenced by inaugural Chemistry, Manufacturing and Controls (CMC) Development and Readiness Pilot (CDRP) programs to expedite commercial manufacturing, US Food and Drug Administration (FDA) approvals and marketing authorizations.

DNA 66

DNA Radiology FDA Approval Development 66

Drug Discovery World

NOVEMBER 13, 2023

Stefan Warmuth, PhD, Vice President, Head CMC, Numab Therapeutics, on: ‘Update on Numab’s affinity-balanced PD-L1x4-1BBxHSA trispecific tumour-targeted immunotherapy’. Fabian Mohr, PhD, Vice President Research & Development, IBA Lifesciences, on: ‘Developing a robust affinity tag platform using engineered streptavidin’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Novel approaches This session will feature two luncheon presentations: Nicholas Field, Principal Scientist, Purification Development, Lonza, on: ‘Tailored CMC solutions to overcome the challenges in bispecific, Fab and Fc-fusion protein development programs’.

Engineer 52

Engineer Antibody Protein In-Vivo 52